Structured evidence table for Inositol Anxiety Randomized Trial, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Inositol Anxiety Randomized Trial | Objective: The primary aim of this study is to comprehensively review existing evidence and assess the impact of nutritional supplements on the performance of esports athletes, including cognitive, psychological, and gaming aspects. | 1 | Huang D (2025) | Nutritional supplements to improve esports player performance: a systematic review of randomized controlled trials. |
| Inositol Anxiety Randomized Trial | The methodological quality of the included studies was assessed using the Physical Therapy Evidence Database (PEDro) scale. | 1 | Huang D (2025) | Nutritional supplements to improve esports player performance: a systematic review of randomized controlled trials. |
| Inositol Anxiety Randomized Trial | Based on existing evidence, some nutritional supplements are associated with three aspects of competitive performance among esports players: 1) Esports players demonstrate significant improvements in attention and executive function, which are closely related to gaming. | 1 | Huang D (2025) | Nutritional supplements to improve esports player performance: a systematic review of randomized controlled trials. |
| Inositol Anxiety Randomized Trial | The performance of esports athletes depends not only on daily skill training but also on cognitive function, reaction speed, and psychological mood. | 1 | Huang D (2025) | Nutritional supplements to improve esports player performance: a systematic review of randomized controlled trials. |
| Inositol Anxiety Randomized Trial | The global prevalence of PCOS increased from 36.7 to 69.5 million between 1990 and 2021. | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Inositol Anxiety Randomized Trial | Emerging evidence underscores that OS is not a mere byproduct of metabolic imbalance but a central driver that disrupts insulin signaling, amplifies androgen biosynthesis, and impairs folliculogenesis (,). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Inositol Anxiety Randomized Trial | Low-dose variants of OCPs have been observed with an increased risk of myocardial infarction and cardiovascular arterial disease (). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Inositol Anxiety Randomized Trial | 1 2 3 4 5 Polycystic ovary syndrome (PCOS) represents one of the most complex endocrine-metabolic disorders affecting women of reproductive age, characterized by a collection of reproductive, metabolic, and psychological manifestations (,). | 3 | Subakathulla Sumayyah (2026) | Redox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails? |
| Inositol Anxiety Randomized Trial | Background Overactive bladder (OAB) is a common functional disorder in paediatric populations and is associated with significant psychological burden and impaired quality of life. | 4 | Colletti A (2026) | Impact of Adjunctive Myo-Inositol and Magnesium Therapy on Paediatric Overactive Bladder: A Retrospective Analysis. |
| Inositol Anxiety Randomized Trial | Emerging evidence suggests that targeting metabolic dysfunction, oxidative stress, and neuromuscular excitability may provide additional therapeutic benefit. | 4 | Colletti A (2026) | Impact of Adjunctive Myo-Inositol and Magnesium Therapy on Paediatric Overactive Bladder: A Retrospective Analysis. |
| Inositol Anxiety Randomized Trial | Results by day 112, complete daytime continence was achieved in 61.7% of patients in group a and 48.3% in group b (absolute risk difference 13.4%; nnt ≈ 7.5; p = 0.14). | 4 | Colletti A (2026) | Impact of Adjunctive Myo-Inositol and Magnesium Therapy on Paediatric Overactive Bladder: A Retrospective Analysis. |
| Inositol Anxiety Randomized Trial | Although oxybutynin is widely used as first-line pharmacological therapy, a substantial proportion of children exhibit incomplete symptom control or limited tolerability. | 4 | Colletti A (2026) | Impact of Adjunctive Myo-Inositol and Magnesium Therapy on Paediatric Overactive Bladder: A Retrospective Analysis. |
Source documents